Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.

利拉鲁肽 医学 微量白蛋白尿 达帕格列嗪 尿酸 糖尿病 内科学 随机对照试验 2型糖尿病 内分泌学 2型糖尿病
作者
Ting Ou,Wen Wang,Huijuan Yong,Hao Hong,Rongxuan Wang,Xinyu Dai,Dibin Wang,Yuntao Li
出处
期刊:PubMed [National Institutes of Health]
卷期号:28 (6): 14-21 被引量:3
链接
标识
摘要

Context: Diabetes mellitus (DM) represents an emerging epidemic, poses serious threats to human health, and can seriously compromise patients' quality of life (QoL). Currently, no cure exists for DM. Some studies have found that both liraglutide and dapagliflozin have great therapeutic potential in preventing and treating DM and its complications. Objective: The study aimed to examine the impact of liraglutide plus dapagliflozin on high uric acid (UA) and microalbuminuria (MAU) in patients with diabetes mellitus (DM) complicated with metabolic syndrome (MS). Design: The research team designed a randomized controlled trial. Setting: The study took place at the Second Affiliated Hospital of Nanjing Medical University in Nanjing, Jiangsu, China. Participants: Participants were 125 patients with DM complicated with MS who were treated in the outpatient clinic of the endocrinology department at the hospital between January 1, 2020 and December 31, 2021, with 68 in the intervention group and 57 in the control group. Intervention: The intervention and control groups both received 0.6 mg of liraglutide. The intervention group also received 5 mg of dapagliflozin once a day. The dosages were increased at one week after baseline based on the participant's condition. Outcome Measures: Therapeutic effects, glycolipid metabolism, inflammation, uric acid (UA), microalbuminuria (MAU), cardiac function, and quality of life (QoL) were compared between the two groups. Results: Postintervention, the clinical efficacy was significantly higher in the intervention group than in the control group. The intervention group had significantly lower glycolipid metabolism and inflammatory-factor levels than the control group UA and MAU had declined in both groups but were significantly lower in the intervention group. The left ventricular ejection fraction (LVEF) increased and the left ventricular end diastolic diameter (LVEDd) decreased in both groups, but the intervention group had significantly greater changes as compared with those in the control group. The intervention group was also superior to the control group in patients' QoL. Conclusions: Liraglutide plus dapagliflozin has highly therapeutic effect for patients with DM complicated with MS and can effectively reduce UA and MAU levels. The current research team will launch a more comprehensive analysis as soon as possible to obtain the most accurate results.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
西柚完成签到,获得积分10
刚刚
阿申爱乐的应助被kiki采纳,获得100
刚刚
刚刚
1秒前
3秒前
3秒前
4秒前
无花果的应助被wwq采纳,获得10
4秒前
4秒前
苏蔚完成签到,获得积分10
6秒前
6秒前
尼奥完成签到 ,获得积分10
6秒前
7秒前
周一发布了新的文献求助30
7秒前
nuodei发布了新的文献求助10
8秒前
icecream612发布了新的文献求助10
8秒前
花花完成签到,获得积分10
8秒前
清爽秋荷发布了新的文献求助10
8秒前
wang发布了新的文献求助10
10秒前
10秒前
深情安青的应助被巧克力蛋高采纳,获得10
11秒前
13秒前
热情的孤容完成签到,获得积分10
13秒前
善良绮菱发布了新的文献求助30
14秒前
传奇3的应助被个性的涑采纳,获得10
14秒前
blqs完成签到,获得积分20
14秒前
15秒前
FAN发布了新的文献求助50
15秒前
幽默的雨琴完成签到 ,获得积分10
15秒前
YANG完成签到 ,获得积分10
15秒前
猪猪猪发布了新的文献求助10
16秒前
yang发布了新的文献求助30
16秒前
17秒前
还见似帝尧完成签到,获得积分10
18秒前
mani完成签到,获得积分10
18秒前
李爱国的应助被pp1015采纳,获得10
18秒前
19秒前
淡淡大山发布了新的文献求助10
20秒前
秋风的应助被JiaYouguo采纳,获得20
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194041
求助须知:如何正确求助?哪些是违规求助? 9579979
关于积分的说明 21868799
捐赠科研通 7793641
什么是DOI,文献DOI怎么找? 3437477
关于科研通互助平台的介绍 2560942
邀请新用户注册赠送积分活动 2484251